Bionano Genomics
Bionano Genomics, Inc. is a biotechnology company focused on genome mapping and analysis. It develops and markets the Saphyr system, an advanced platform designed for ultra-sensitive and specific detection of structural variations in DNA, such as insertions, deletions, and translocations, which are often linked to genetic disorders and diseases, including cancer. The Saphyr system employs optical genome mapping technology, allowing for direct visualization and analysis of long DNA molecules without relying on sequencing. This capability provides researchers and clinicians with critical insights into the structural variations within genomes, enhancing the understanding of disease mechanisms and supporting the development of personalized treatment strategies. Bionano Genomics also offers essential reagents and data solutions, including Bionano prep kits, labeling kits, and software tools for comprehensive experiment management. Its products are primarily sold to academic and governmental research laboratories, as well as pharmaceutical, biotechnology, and contract research organizations across multiple regions, including North America, Europe, and Asia. Founded in 2003 and headquartered in San Diego, California, the company was previously known as BioNano Genomics, Inc. until its name change in July 2018.
Purigen Biosystems
Acquisition in 2022
Purigen Biosystems, Inc. specializes in the manufacture of an ionic purification system aimed at the extraction and purification of nucleic acids from biological samples. Utilizing isotachophoresis, a technique that employs electric fields for the separation and purification of nucleic acids, the company offers an innovative solution that is agnostic to nucleic acid size or sequence. This technology is particularly effective for challenging sample types, including formalin-fixed, paraffin-embedded (FFPE) tissues and low cell counts. Purigen's automated platform processes various biological samples such as mammalian cells, tissue biopsies, plasma, blood, and buccal swabs, delivering ready-to-use DNA or RNA for applications like qPCR, microarray, and next-generation sequencing (NGS) preparations. Founded in 2012 and based in Pleasanton, California, Purigen operates as a subsidiary of Agilent Technologies, providing researchers with a fast and efficient alternative for nucleic acid purification.
BioDiscovery
Acquisition in 2021
BioDiscovery, Inc. is a scientific software company based in El Segundo, California, specializing in genetic research and genomic analysis. The company develops, markets, and sells a range of software solutions designed for the analysis of data generated from high-throughput microarray and next-generation sequencing technologies. Key products include Nexus Copy Number, which simplifies genetic aberration analysis, Nexus Expression for microarray data analysis, and Nexus DB, a cloud-based repository for sample queries. Additionally, BioDiscovery offers ImaGene, an image analysis software, and NxClinical for clinical case review and reporting. The company also provides training and consulting services, including data analysis and study design. Its software and services are aimed at facilitating drug discovery and diagnostics by enabling effective management, integration, and analysis of genomic data. Founded in 1997, BioDiscovery continues to support advancements in clinical research and cancer treatment.
Lineagen
Acquisition in 2020
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, that specializes in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism spectrum disorders (ASDs). Founded in 2002, Lineagen offers several key products, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes associated with autism, and NextStepDx PLUS, a genetic sequencing test that detects small genomic alterations. Additionally, the company provides M-CHAT.org, an online tool for developmental screening. Lineagen aims to improve outcomes for individuals affected by complex diseases through early diagnosis and intervention, leveraging extensive proprietary research and access to the Utah Population Database to enhance its understanding of genetic contributions to these conditions. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.